Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies that allow screening of dozens of genes in tens of thousands of individuals with high specificity and sensitivity. The decision of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the potential impact on the field of neuroscience. 
Recent exome (and genome) sequencing studies of families have aimed to comprehensively discover genetic variation to identify the most likely causal mutation in patients with disease. Sequencing studies of parent-proband trios for probands with intellectual disability (ID) 1,2 , autism spectrum disorder (ASD) [3] [4] [5] [6] [7] , schizophrenia (SCZ) [8] [9] [10] and epilepsy 11 have all suggested that de novo point mutations are important in pediatric and adult disorders of brain development ( Table 1) . The relative contribution of de novo mutations to each disorder remains to be determined but appears to correlate well with the degree of reduced fitness or fecundity of the given condition 12 . However, not only de novo events but also rare inherited copy number variants (CNVs) can have an effect on fecundity, though their overall effect on fecundity is still debated 13 . Biologically, 75-80% of de novo point mutations arise paternally 3, 14 , likely as a result of the greater number of cell divisions in the male germline lineage than in the female lineage. These findings are consistent with some epidemiological data that find advancing paternal age to be a significant predictor of ASD, ID and SCZ [15] [16] [17] and argue for the need to properly control for paternal age when comparing mutation rates between probands and siblings. The importance of de novo and private rare mutations is especially important clinically, as there are now reports of diagnostic yields ranging from 10-55% for select (usually the most severe) groups of patients with ID 1,2 and epilepsy 18 , in addition to resolution of unsolved Mendelian disorders 19 . It is clear that next-generation sequencing approaches have provided powerful tools for identifying genes harboring potentially pathogenic mutations. Deciding which genes to pursue, however, is not always self-evident because follow-up research and diagnostic studies are critical to understanding the full contribution of a particular mutation to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes identified through sequencing studies, show emerging trends and highlight potential strategies for subsequent functional characterization of these neurodevelopmental genes. We focus on lessons learned from 11 recent studies that report 2,368 de novo mutations from a total of 2,358 probands and 600 de novo mutations from 731 controls ( Table 1) . The bulk of the data originate from sequencing studies of parents and probands with ASD, ID and epileptic encephalopathies, but more recent studies have also highlighted the importance of de novo mutations in SCZ. There is evidence that de novo mutations, particularly disruptive mutations, occur in the same genes despite the nosological distinction for these different diseases. For the purpose of this Review, we collectively term these diseases 'neurodevelopmental disorders' but recognize that some, especially adult-onset diseases such as SCZ, may have etiologic components that are not neurodevelopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible 'new disease genes' responsible for a given neurodevelopmental phenotype is the recurrence of de novo mutations in the same gene, along with the absence of such mutations in healthy controls. This rule follows the precedent established for the discovery of pathogenic de novo CNVs during the last decade, with the highest priority given to recurrent mutations that lead to a complete loss of function of one of the parental copies of the gene. Up to ten independent reports of de novo mutations in SCN2A and nine independent reports of de novo mutations in SCN1A and STXBP1 have been described (Tables 2 and 3 ). Strikingly, de novo mutations in those genes have so far been found exclusively in probands and never in controls. Simulation data suggest that at least two but certainly three or more recurrent de novo loss-of-function (LoF) events (that is, predicted nonsense, frameshift or canonical splice site mutations) r e v i e w Perhaps the most striking examples are recurrent identical de novo mutations in the same gene. Across the various studies, such identical recurrences have already been observed for six genes (ALG13, KCNQ3, SCN1A, CUX2, DUSP15 and SCN2A; Table 4 ). Such events are exceedingly unlikely, with estimates of identical recurrences in ALG13 and SCN2A calculated at P = 7.77 × 10 −12 and P = 1.14 × 10 −9 , respectively, in the case of epilepsy 11 . Most of these estimates of significance, however, assume a random mutation process. Yet mutational hotspots certainly exist, and recurrence of the same mutation cannot be taken as proof positive of an association.
The clinical significance of most de novo mutations discovered in patients remains unclear. For most genes, only a single de novo mutation has been identified. Nevertheless, on the basis of the observation that de novo LoF mutations occur two to three times more frequently in ASD probands than in unaffected siblings, it is now estimated that a large fraction of these singletons will be relevant to disease etiology. When considering all studies in aggregate, de novo LoF mutations are observed significantly more in cases than in controls ( Table 1; Fisher's exact test, P = 0.0062). The interpretation of recurrent missense mutations, however, represents a greater challenge. Sanders et al. 4 estimated that four missense de novo mutations in the same genes would be required in simplex autism to exceed a chance finding; this was based on a cohort size of up to 2,000 with an estimated locus heterogeneity of 1,000 ASD risk loci. Given the extreme locus heterogeneity of diseases such as ASD and ID, other strategies have been adopted to prioritize likely causal genes. High-throughput targeted are unlikely to occur by chance, making such genes outstanding candidates ( Table 2) 7 .
The frequency of recurrence is dependent on the extent of locus heterogeneity associated with each disease. Leveraging observed recurrences of de novo mutations (Fig. 1) , researchers believe that diseases such simplex autism and SCZ arise from mutations in >500 genes, while studies of severe ID and epileptic encephalopathies (infantile spasms and Lennox-Gastaut subtypes) suggest lower heterogeneity. Such estimates should be considered only rough approximations at this point because they are highly dependent upon the fraction of de novo mutations that are in fact pathogenic, as well as ascertainment biases in sample collection (Fig. 1) . In this regard, several of the candidate genes with highest numbers of recurrent mutations have been observed in patients with epilepsy 11 , ID 1,2 and ASD [3] [4] [5] [6] [7] . This may not be surprising in light of the comorbidity of these diseases and if one accepts that heterogeneity is lower for epilepsy-related disorders than for ASD, SCZ or ID. In such a scenario, sequencing of even a modest number of epilepsy cases delivers recurrent mutations more frequently than more broadly defined developmental delay or ASD 11, 18 . One study of SCZ, for example, highlighted four recurrently mutated genes, but perhaps more remarkably, the same study identified overlapping genes with those implicated in ASD when focusing on prenatally expressed genes 9 . The stronger overlap between ASD, ID and epilepsy and yet limited overlap with SCZ ( Table 2) could be largely because only a subset of the latter disease stems from a neurodevelopmental origin. npg r e v i e w multiplexed resequencing technologies, such as molecular inversion probes, have been employed to screen ~50 candidate genes in thousands of patients and controls 3, 18 . Such approaches are scalable, inexpensive (less than $1 per gene per sample), sensitive and specific, increasing by an order of magnitude the number of patients that can be screened. The strategy was particularly useful in discovering a burden of de novo LoF mutation of CHD8 associated with ASD 20 . The relatively ease in detecting de novo mutations allows rapid identification of potential candidate genes; the number of cases that are required to make these findings statistically significant ( Fig. 1) can be lower for the genes that are mutated exclusively in a large number of patients when compared to standard case-control studies 21 .
Previous evidence of overlap with pathogenic CNVs
Another strategy has been to compare patterns of CNVs in patient and control populations to prioritize genes ( Fig. 2 ) 22 . Extensive CNV morbidity maps have been developed for tens of thousands of children with autism, ID and epilepsy, helping to define pathogenic regions of dosage imbalance in the human genome [23] [24] [25] [26] . Overlapping deletions in such collections occasionally refine the smallest region of overlap, highlighting a modest number of candidate genes. Recurrent de novo point mutations in a gene within such a region with CNV burden substantially increases the likelihood that LoF of the gene is responsible for a phenotype. O'Roak et al. 3 and Rauch et al. 2 each discovered, for example, LoF point mutations for SETBP1-a gene where a significant enrichment for deletion CNVs has been seen in patients with overlapping neurodevelopmental phenotypes but not in controls. Similar patterns have recently been observed for DYRK1A and MBD5 (Fig. 2) , including reports of balanced but gene-disrupting chromosomal translocations 27 . Such information has been used to compute haploinsufficiency scores 2, 28 to strengthen the case for causality of de novo LoF mutations (Fig. 2) .
Position of the mutation in the protein
More than 60% of de novo mutations discovered from exome sequencing projects are missense mutations ( Table 1) . Distinguishing pathogenic signal from the background of benign mutations is an active area of research. For genes for which previous CNVs or LoF mutations were described, 'severe' missense mutations are also likely to result in a dosage effect. However, there are examples, usually from clinically well-defined neurodevelopmental syndromes, showing that missense mutations result in different outcomes on the basis either of the protein domain they affect, the position in the gene (for example, the N or C terminus of the resulting protein) 29 or their potential to modify the normal function of the protein. Examples of this last include gain-of-function (GoF) mutations and LoF mutations in the same gene that result in different phenotypic outcomes 30, 31 . SETBP1 GoF in a degron sequence (ubiquitination motif) results in the rare but well-defined Schinzel-Giedion syndrome 32 , while deletions or LoF mutations may result in a distinct and milder phenotype comprising ASD or ID with speech delay and other features 2, 3, 33, 34 .
Other examples include different phenotypic effects dependent on the location of the mutation: early truncating and missense mutations in NOTCH2 are known to cause Alagille syndrome 35 , while truncating events restricted to the last exon escape nonsense-mediated decay and result in Hajdu-Cheney syndrome 36, 37 .
Mutational burden among healthy individuals
One approach to prioritizing missense mutations leverages evolutionary conservation by assigning 'mutability scores' per gene or even at the base-pair level. O'Roak et al. 3 , for example, established an evolutionary mutation score per human gene based on the humanchimpanzee divergence and the size of a gene. Similarly, the Epi4k Consortium used a gene-specific mutation rate based on a per-base score 38 ; this score was, however, not based on human-chimpanzee evolution but made use of human-specific polymorphism data. A recent publication used rare variant data from healthy individuals and offers a new integrative annotation tool for noncoding variants 39 . The wealth of available control exome sequence data can also be used to estimate the (rare) variant load per gene (and distribution). For example, the analysis of data generated from sequencing 6,500 'control' exomes as part of the ESP6500 data release has been used to define the load of LoF mutations per gene 2 and to prioritize >4,000 human genes that are most intolerant of variation 11 ; details on the respective samples can be obtained from the Exome Variant Server (http://evs.gs.washington.edu/EVS/). Another approach uses npg r e v i e w random mutation modeling 40 to calculate the likelihood that observed (de novo) mutations have a damaging effect. Similar prioritizations are provided by tools that score individual mutation severity (SIFT, PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which can be adapted to a gene-based prioritization score from genome-wide data 41 . These population data provide a powerful unbiased approach to home in on genes that are likely to be among the most penetrant because of the complete absence of disruptive variation in the general population (for example, CHD8 or DYRK1A). A critical aspect of such analyses is the reliability of a particular gene model. Most human genes show evidence of alternative splice forms, many of which have no known function. Apparent hotspots of mutation for a particular exon (often exon-intron boundaries) in both cases and controls may suggest misannotation, the presence of a processed pseudogene or an alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene candidates for further disease association and characterization has been to identify specific biological networks of genes enriched in cases as compared to controls. Although this approach cannot be used unequivocally to define causality, membership of a specific gene in a particular protein-protein interaction (PPI) or coexpression network may increase the likelihood of its association with disease. Numerous studies have reported significant enrichment of both de novo CNV and single-nucleotide variant (SNV) mutations in particular pathways 3, 4, 42, 43 . O'Roak et al. 3 , for example, reported a significant enrichment of de novo disruptive autism mutations among proteins associated with chromatin remodeling and β-catenin and WNT signaling-a finding that was replicated in a follow-up resequencing study of more than 2,400 probands. One recent instance, in which membership of a new candidate gene in a PPI network led to the discovery of an autism-associated gene, is ADNP. A single ADNP LoF mutation was initially observed in exome sequencing studies.
Although the observed mutation frequency in this gene did not reach statistical significance when cases and controls were compared 20 , it was strongly implicated in the PPI network originally defined by O'Roak et al. 3 Targeted resequencing experiments combined with clinical exome sequencing identified several more cases with de novo mutations and remarkably similar phenotypes representing a new SWI-SNF-related autism syndrome (Fig. 3 ) 44 . Notably, many of the genes implicated in the β-catenin pathway have also been described as mutated in patients with ID 1 but not in patients with SCZ. Similarly, an enrichment of genes interacting with FMR1 (also known as FMRP)-the gene responsible for fragile X syndrome-has been reported with de novo mutations in ASD 5 , epilepsy 11 and, most recently, SCZ 10, 45 . Whether this observation is due to the relative high incidence of cases that also presented with comorbid ID remains to be determined. In addition to PPI networks, studies of coexpression have shown enrichment for specific spatio-temporal patterns of expression. A study of coexpressed genes affected by de novo mutations reported an enrichment in fetal prefrontal cortical network in SCZ 8 , which is in line with the finding by Xu et al. 9 that genes with higher expression We estimate the number of fully penetrant genes that can explain disease once mutated, based on a de novo model using the 'unseen species problem'. We consider all recurrent missense or LoF de novo mutations pathogenic, as well as a defined fraction of mutations in genes observed just once (because it is unlikely that all de novo mutations are pathogenic). The ratio between genes mutated recurrently and the rate of singleton mutations suggests an estimate for the true number of genes pathogenic when mutated. Including more singleton mutations increases the fraction of each disorder explained by single de novo SNVs at the cost of including more genes as pathogenic. Initial exome sequencing studies of epilepsy and ID focused on specific pediatric subtypes or the most severe cases; thus, the number of generalized epilepsy-or ID-associated genes is likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exomewide significance of 2.6 × 10 −6 ). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes, under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account when determining significance. 46 working with a few highconfidence sets of ASD-associated genes as seeds reported a convergence of the expression of these genes in deep-layer cortical projection neurons (layers 5 and 6) in midfetal development. Another analysis using a larger set of ASD and ID risk genes suggested translational regulation by FMR1 and an enrichment in superficial cortical layers 43 . Implicit in these types of analyses is the notion that, while more than 1,000 genes may be responsible for ASD or ID, in the end the genes will converge on a few highly enriched networks of related genes. It is possible that molecular therapies targeted to the network at a specific stage of development, as opposed to the individual gene, may be beneficial to specific groups of patients. Related to this, it is intriguing that several recurring genes and pathways that have been implicated in neurodevelopmental disease have also been associated with different forms of cancer (Fig. 4) 47 . While clear-cut examples such as the mutation of the tumor suppressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris syndrome) in neurodevelopmental disease have been extensively reviewed 48 , more recent exome sequencing data from patients with neurodevelopmental disease suggest new links. The most striking observation here is the identical point mutations reported to cause cancer when mutated somatically and severe neurodevelopmental syndromes when mutated in the germline. Examples include the identical mutations in SETBP1 (ref. Table 1) . It is important to stress that this is an observation at an individual gene level and should not be translated to an epidemiological link: that is, this cannot be generalized to speculate that patients with neurodevelopmental disorders in these specific genes will all be at a higher risk for certain cancer types. Instead, it is likely that this convergence represents a selection of genes that are fundamental to cell biology (for example, cell proliferation and/or membership in multi-subunit complexes associated with chromatin remodeling). There is also the distinct possibility of pleiotropy; that is, the genes and pathways have completely unrelated functions, explaining developmental defects and cancer independently. Therefore, de novo mutations in those genes can result in different outcomes depending on timing, genetic background and cellular context. Nevertheless, there may be advantages to integrating sequence data from patients with neurodevelopmental disease and massive sequencing programs devoted to the discovery of somatic mutations in tumors-for example, the International Cancer Genome Project 52 . It is possible that these intersections will help to further prioritize genes important in both cellular development and neurodevelopment.
Phenotypic similarity of recurrent de novo mutations Although essential, statistical support of recurrent mutations is not the sole arbiter in determining pathogenicity of particular mutations and genes. In particular, it is important to consider the phenotypic presentation and overlap of the individuals with the same presumptive underlying genetic lesion. In this regard, we note that 64 and a deletion syndrome in humans 27, 63 . MBD5 has been implicated as the causal gene for the 2q23.1 deletion syndrome associated with epilepsy, autism and ID 91, 92 .
a b npg r e v i e w many of the initial studies are likely to be enriching for the most severe cases because ascertainment is clinical as opposed to population based. As a result, initial estimates of penetrance may be overestimated and phenotypic heterogeneity underestimated. Nevertheless, identification of clinically recognizable syndromes or sets of phenotypic features has historically been used to strengthen the case for a particular gene's involvement. In the past, gene discovery was usually driven by detailed description of a particular syndrome (for example, fragile X or Rett syndrome), followed by a systematic hunt for the mutated gene. Recognition of clinical subtypes, however, is now beginning to occur after mutation and gene discovery. In the case of PACS1 (ref. 53) , for example, identical de novo mutations result in patients with a strikingly similar phenotypic outcomes (Fig. 3) . Such clinical discernment, now more than ever, requires the expertise of the clinician. It should be noted, however, that not all genes when mutated will show a phenotypic convergence; they rather may be much more variable in their phenotypic presentation. For example, mutations in ARID1B can either lead to isolated ID 54 or syndromic form of ID with a recognizable phenotype known as Coffin-Siris syndrome 48, 55 . The type of mutation may be critical in this regard. It is noteworthy that patients with LoF mutations of SCN2A described in autism cohorts 4 do not show epilepsy, in contrast to multiple recurrent missense mutations identified among epileptic encephalopathies or, more specifically, the infantile-spasms or Lennox-Gastaut subtype. Similarly, de novo missense mutations in CHD2, SETD5 and SLC6A1 have been reported in patients with ASD, yet frameshift mutations in the same genes are seen in patients with ID but without ASD features 2 . There are several considerations regarding genotypephenotype correlations.
First, some of the classically defined neurodevelopmental syndromes may present with broader (or milder) phenotypes as defined by initial clinical case reports 2 . There is evidence that the genetic background on which these mutations occur substantially influences phenotypic outcome [56] [57] [58] .
Second, genotype-first approaches using current genomic technologies followed by 'reverse phenotyping' are beginning to define more subtle syndromes that are still opaque in large umbrella cohorts such as ASD or ID 13 . Some examples include macrocephalic subtypes of ASD or ID caused by mutations in PTEN and CHD8 (refs. 20,59 ) and developmental delay/ID and epilepsy caused by de novo mutations in SCN2A (refs. 1,2,18) .
Third, after discovery of potential causative mutations, more detailed and standardized phenotyping assessments are necessary to eliminate disease ascertainment biases. As patients with a specific mutation will individually be rare, greater coordination, including patient recontact, will need to occur across clinical research centers.
Biological impact in model organisms
Detailed phenotypic characterization of patients is an important first step in modeling mutations in other organisms. Indeed, additional support for a gene's involvement in disease is often provided by related pathologies in these model organisms and may be used to rapidly prioritize genes for further study, as well as to provide further insight into function. In many cases, mouse models 60 or Drosophila mutant lines 61 already exist and neurologic phenotypes have been, at least partially, documented. For example, recurrent LoF mutations of ADNP (activity-dependent neuroprotective peptide) were recently described in patients with autism and ID 3 . Heterozygous knockout mice show a neuronal and glial pathology associated with reduced cognitive function 62 , and this phenotype was recognized in mouse models before the association with human disease. Similarly, heterozygous deletions or mutations of DYRK1A in humans 20, 63 , mice 64 and fruit flies 65 all show a phenotype of reduced brain volume associated with 25, 57 . Even for the protein-coding component, sequence discovery is incomplete, with 5-10% of the exons either being missed or insufficiently captured to confidently call genetic variation. The bias is particularly pronounced for genes mapping to high-GC-content regions of the genome, where as many as 20-30% of exons may be insufficiently covered. The sequencing technology also introduces biases against certain types and classes of mutation. The discovery of indels is largely regarded as incomplete because of difficulties associated with mapping short sequence reads in low-complexity regions 70 . Although there have been recent methods for calling smaller CNVs, validation experiments indicating specificity and sensitivity are still far from ideal 71, 72 . The development of new sequencing chemistries and platforms that can cheaply and in a high-throughput manner access these regions of the genome should remain a high priority.
There is another level of reduced sensitivity related to the timing of de novo mutations. It is increasingly recognized that postzygotic de novo mutations-that is, mutations in somatic statemay be important in many more disorders 73 . While the importance of somatic de novo mutations has been recognized for many years in the field of cancer genetics 52, [74] [75] [76] , we are only starting to appreciate its prevalence in neurodevelopmental disease 77, 78 . Several exome studies report that individual de novo mutations are likely to have occurred postzygotically, with estimates ranging from 1 to 2% of new mutations based on analysis of DNA derived from blood. O'Roak et al. 3 , for example, have shown that ~4% (9 of 209 cases) of de novo mutations were likely to have occurred postzygotically. Mosaic mutations have been observed as a more general theme for CNVs but not yet linked systematically to disease 79 . More sensitive technologies 80, 81 , as well as access to more clinically relevant tissue types, are required to identify lower level mosaicism. For defined disorders with isolated neurologic involvement, this may never be possible if the mosaicism is restricted to neuronal subtypes in the brain.
Besides technical hurdles, there is the daunting prospect of the extreme locus heterogeneity of these diseases. This raises the distinct possibility that a recurrent de novo mutation in a second patient will never be seen again in the same clinic. This can be partially overcome by developing new models for data sharing (for example, de novo variant databases) and generating larger sample collections of patients (>50,000) that may be screened in follow-up targeted resequencing experiments. This requires a shift toward a more integrated and collaborative model of clinical and basic research. Successful models of clinical laboratory cooperation and standardization have already been established for the exchange of CNV data-for example, the International Standards for Cytogenomic Arrays (ISCA) Consortium-and there is momentum for doing the same for exome and genome sequence data sets-for example, the International Collaboration for Clinical Genomics (ICCG) 24 . The sheer size of the data set (petabytes), ever-changing advances in sequencing technology and the importance of standardized call sets, however, pose major challenges.
Although sporadic mutations have been the focus of this Review, the importance of inherited mutations should not be underestimated. There is, in fact, compelling evidence that such variation contributes substantially to these diseases 45, 72, 82, 83 . While specific gene effects are much more difficult to tease apart in the general population owing to the genetic heterogeneity of these diseases 45 , other approaches, such as studies of consanguineous families, have identified many candidate risk genes under a recessive disease model [84] [85] [86] . It should also be noted that the effect size and penetrance for many of the recurrent de novo mutations is not yet known. For autism, de novo mutations have been thought to collectively increase risk 10-to 20-fold for up to 20% of patients with disease. It is likely that in some cases a rare variant will be necessary but not sufficient to confer the phenotype, requiring that both inherited and de novo mutations be jointly considered in order to understand their impact, as has been noted for some CNV risk variants 57, 87 . Understanding the gender bias, which is particularly pronounced for ASD and ID, will require integrating inherited and de novo mutations from both the X chromosome and autosomes. Data from CNVs as well as SNVs suggest that the carrier burdens of males and females differ significantly 42, 72, 88, 89 . The evidence suggests that healthy females are more likely to be carriers of deleterious mutations and, therefore, protected against such diseases. Perhaps sex-dependent modifiers are responsible for slightly different diagnostic boundaries for neurodevelopmental disorders between male and female patients.
Because the physiological function of many of the genes linked to disease are yet unknown, it will be necessary to perform systematic studies to understand their specific role in neurodevelopment. The sheer volume of high-impact genes will probably necessitate large-scale model organism knockouts in Drosophila, zebrafish and mouse 60, 66 , industrial-level development of induced pluripotent stem cell lines and neuronal differentiation protocols 90 , as well as massive screens using mass spectrometry to identify protein interaction partners. All of these approaches have their own limitations. For example, it is an open question how well knockouts will model neurodevelopmental diseases such as ASD or ID because most of the known effects in humans occur in the heterozygous state and most knockout phenotypes are typically studied as homozygous LoF mutations. Many phenotypic aspects of complex neuropsychiatric and neurobehavioral disease will not be amenable to model systems, further limiting such npg r e v i e w functional approaches. Notwithstanding these challenges, we are in a golden age of 'neurogene' discovery that promises not only to improve our understanding of disease but to provide fundamental insight into the biology of human brain development. 
